Abstract
BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.
METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.
RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).
CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.
| Original language | English |
|---|---|
| Journal | Journal of the National Cancer Institute |
| Volume | 108 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2016 |
Fingerprint
Keywords
- Journal Article
Cite this
Selenium and Prostate Cancer : Analysis of Individual Participant Data From Fifteen Prospective Studies. / Allen, Naomi E.; Travis, Ruth C.; Appleby, Paul N.; Albanes, Demetrius; Barnett, Matt J; Black, Amanda; Bueno-de-Mesquita, H Bas; Deschasaux, Mélanie; Galan, Pilar; Goodman, Gary E.; Goodman, Phyllis J.; Gunter, Marc J.; Heliövaara, Markku; Helzlsouer, Kathy J; Henderson, Brian E.; Hercberg, Serge; Knekt, Paul; Kolonel, Laurence N.; Lasheras, Christina; Linseisen, Jakob; Metter, E. Jeffrey; Neuhouser, Marian L.; Olsen, Anja; Pala, Maria Valeria; Platz, Elizabeth A; Rissanen, Harri; Reid, Mary E; Schenk, Jeannette M; Stampfer, Meir J; Stattin, Pär; Tangen, Catherine M; Touvier, Mathilde; Trichopoulou, Antonia; van den Brandt, Piet A; Key, Timothy J.; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.
In: Journal of the National Cancer Institute, Vol. 108, No. 11, 11.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Selenium and Prostate Cancer
T2 - Analysis of Individual Participant Data From Fifteen Prospective Studies
AU - Allen, Naomi E.
AU - Travis, Ruth C.
AU - Appleby, Paul N.
AU - Albanes, Demetrius
AU - Barnett, Matt J
AU - Black, Amanda
AU - Bueno-de-Mesquita, H Bas
AU - Deschasaux, Mélanie
AU - Galan, Pilar
AU - Goodman, Gary E.
AU - Goodman, Phyllis J.
AU - Gunter, Marc J.
AU - Heliövaara, Markku
AU - Helzlsouer, Kathy J
AU - Henderson, Brian E.
AU - Hercberg, Serge
AU - Knekt, Paul
AU - Kolonel, Laurence N.
AU - Lasheras, Christina
AU - Linseisen, Jakob
AU - Metter, E. Jeffrey
AU - Neuhouser, Marian L.
AU - Olsen, Anja
AU - Pala, Maria Valeria
AU - Platz, Elizabeth A
AU - Rissanen, Harri
AU - Reid, Mary E
AU - Schenk, Jeannette M
AU - Stampfer, Meir J
AU - Stattin, Pär
AU - Tangen, Catherine M
AU - Touvier, Mathilde
AU - Trichopoulou, Antonia
AU - van den Brandt, Piet A
AU - Key, Timothy J.
AU - Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group
N1 - © The Author 2016. Published by Oxford University Press.
PY - 2016/11
Y1 - 2016/11
N2 - BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.
AB - BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade.METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided.RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08).CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.
KW - Journal Article
U2 - 10.1093/jnci/djw153
DO - 10.1093/jnci/djw153
M3 - Article
C2 - 27385803
VL - 108
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 11
ER -